<DOC>
	<DOC>NCT00530699</DOC>
	<brief_summary>The purpose of this study is to assess safety and tolerability of multiple ascending doses of AZD1152 and to assess effect of AZD1152 on the rate of complete remission in patients with relapsed acute myeloid leukaemia who are not considered to be suitable for standard chemotherapy.</brief_summary>
	<brief_title>Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>Patients with relapsed or refractory AML for which no standard therapies are anticipated to result in durable remission Newly diagnosed Acute Myeloid Leukemia who are not considered suitable for other treatments. Administration of anticancer agents (other than hydroxyurea) within 2 weeks prior to first dose of study drug, and administration of hydroxyurea within 24 hours prior to first dose of study drug Participation in any other trial with an investigational product within the previous 30 days. Uncontrolled intercurrent illness including, but not limited to, active infection, symptomatic congestive heart failure, cardiac arrhythmia or psychiatric illness/social situations</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Acute Myeloid Leukaemia</keyword>
	<keyword>Phase 1</keyword>
	<keyword>AZD1152</keyword>
</DOC>